MY179214A - Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl]6alpha, 9alpha- difluoro-17alpha-(furan-2-yl)carbonyloxy-11beta-hydroxy-16alpha- methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate - Google Patents

Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl]6alpha, 9alpha- difluoro-17alpha-(furan-2-yl)carbonyloxy-11beta-hydroxy-16alpha- methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate

Info

Publication number
MY179214A
MY179214A MYPI2015704326A MYPI2015704326A MY179214A MY 179214 A MY179214 A MY 179214A MY PI2015704326 A MYPI2015704326 A MY PI2015704326A MY PI2015704326 A MYPI2015704326 A MY PI2015704326A MY 179214 A MY179214 A MY 179214A
Authority
MY
Malaysia
Prior art keywords
oxoandrosta
methylbutyryloxy
carbothioate
ynyl
carbonyloxy
Prior art date
Application number
MYPI2015704326A
Other languages
English (en)
Inventor
Ranchhodbhai Patel Jiten
Chimanlal Patel Gopalkumar
Sanjivkumar Sheth Gaurav
Nandlal Mandhane Sanjay
Trinadha Rao Chitturi
Thennati Rajamannar
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of MY179214A publication Critical patent/MY179214A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MYPI2015704326A 2013-05-28 2014-05-28 Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl]6alpha, 9alpha- difluoro-17alpha-(furan-2-yl)carbonyloxy-11beta-hydroxy-16alpha- methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate MY179214A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1881MU2013 2013-05-28

Publications (1)

Publication Number Publication Date
MY179214A true MY179214A (en) 2020-11-02

Family

ID=51300796

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015704326A MY179214A (en) 2013-05-28 2014-05-28 Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl]6alpha, 9alpha- difluoro-17alpha-(furan-2-yl)carbonyloxy-11beta-hydroxy-16alpha- methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate

Country Status (18)

Country Link
US (1) US9458187B2 (OSRAM)
EP (1) EP3004133B1 (OSRAM)
JP (1) JP6366696B2 (OSRAM)
KR (1) KR20160030085A (OSRAM)
CN (1) CN105431445A (OSRAM)
AU (1) AU2014272640B2 (OSRAM)
BR (1) BR112015029530A8 (OSRAM)
CA (1) CA2912400A1 (OSRAM)
EA (1) EA027831B9 (OSRAM)
ES (1) ES2664019T3 (OSRAM)
IL (1) IL242658A0 (OSRAM)
MX (1) MX2015016283A (OSRAM)
MY (1) MY179214A (OSRAM)
PH (1) PH12015502652A1 (OSRAM)
SG (1) SG11201509680TA (OSRAM)
UA (1) UA117248C2 (OSRAM)
WO (1) WO2014192027A1 (OSRAM)
ZA (1) ZA201508640B (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014272640B2 (en) 2013-05-28 2018-04-05 Sun Pharma Advanced Research Company Limited Methods for treatment of inflammatory conditions using S-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.
CN107428796A (zh) * 2015-01-31 2017-12-01 太阳医药高级研究有限公司 S‑(4‑(3‑氟‑3‑甲基丁酰氧基)丁‑2‑炔基)6α,9α‑二氟‑17α‑(呋喃‑2‑基)羰氧基‑11β‑羟基‑16α‑甲基‑3‑氧代雄甾‑1,4‑二烯‑17β‑硫代羧酸酯的结晶形式
CN106279341A (zh) * 2015-05-11 2017-01-04 正大天晴药业集团股份有限公司 一种糠酸氟替卡松的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA81976B (en) 1980-02-15 1982-07-28 Glaxo Group Ltd Androstane carbothioates
AU2003263575A1 (en) 2002-06-20 2004-01-06 Sun Pharmaceutical Industries Limited Convenient synthesis of s-fluoromethyl 6alpha, 9alpha-difluoro-11beta-hydroxy-16alpha- methyl-17alpha-propionyloxy-3-oxoandrosta-1, 4-diene-17beta-carbothioate
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
AR059216A1 (es) * 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
AU2014272640B2 (en) 2013-05-28 2018-04-05 Sun Pharma Advanced Research Company Limited Methods for treatment of inflammatory conditions using S-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.

Also Published As

Publication number Publication date
EP3004133B1 (en) 2018-03-07
EA027831B9 (ru) 2017-12-29
BR112015029530A8 (pt) 2019-12-17
EP3004133A1 (en) 2016-04-13
IL242658A0 (en) 2016-02-01
AU2014272640A1 (en) 2015-11-26
ES2664019T3 (es) 2018-04-18
JP2016520122A (ja) 2016-07-11
US9458187B2 (en) 2016-10-04
AU2014272640B2 (en) 2018-04-05
EA201592283A1 (ru) 2016-04-29
US20160102117A1 (en) 2016-04-14
SG11201509680TA (en) 2015-12-30
WO2014192027A1 (en) 2014-12-04
KR20160030085A (ko) 2016-03-16
CA2912400A1 (en) 2014-12-04
EA027831B1 (ru) 2017-09-29
BR112015029530A2 (pt) 2017-07-25
JP6366696B2 (ja) 2018-08-01
PH12015502652A1 (en) 2016-03-07
UA117248C2 (uk) 2018-07-10
ZA201508640B (en) 2017-09-27
CN105431445A (zh) 2016-03-23
MX2015016283A (es) 2016-03-11

Similar Documents

Publication Publication Date Title
TR201900038T4 (tr) GPR6'nın tetrahidropiridopirazin modülatörleri.
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
TW201613899A (en) Diazirine compounds and compositions derived therefrom
MX364486B (es) Derivados de piridazinona-amidas.
MX2016002794A (es) Compuestos antiproliferativos.
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
EA201790884A1 (ru) 6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
EA201790885A1 (ru) 6α-АЛКИЛ-6,7-ДИОНОВЫЕ СТЕРОИДЫ В КАЧЕСТВЕ ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ ДЛЯ ПОЛУЧЕНИЯ СТЕРОИДНЫХ МОДУЛЯТОРОВ FXR
EA201790879A1 (ru) 6-альфа-алкил-3,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
BR112015029462A8 (pt) Inibidores de quinase
EA201790881A1 (ru) 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
NZ711192A (en) Process for making benzoxazepin compounds
UA112746C2 (uk) Протиракові стероїдні лактони, ненасичені в положенні 7(8)
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
EA201690227A1 (ru) Азаиндольные соединения, их получение и способы их применения
UA110332C2 (en) Use of 2,3-dihydroxypropyldodecanoate for treatment of seborrhea
UA113988C2 (xx) Спосіб стабілізації бета-напівгідрату штукатурного гіпсу
MX2020000873A (es) Derivados de ácidos biliares marcados isotópicamente.
PH12015502652A1 (en) Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.
EA201591449A1 (ru) Способы получения противораковых композиций
PH12017501360A1 (en) Crystalline form of s-(4-3-fluoro-3-methylbutyryloxy)but-2-ynyl)6a,9a-difluoro-17a,-(fluran-2-yl) carbonyloxy-11b-hydroxy-16a-methy1-3-oxoandrosta-1,4-diene-17b-carbothioate
WO2015075693A8 (en) Process for the synthesis of (11 beta,17alpha)-17-acetoxy-11 -methyl-19-norpregn-4-en-3,20-dione
EA201270727A1 (ru) Пуриновые соединения